Axsome Therapeutics Reports the First Patient Dosing of Solriamfetol in the P-III Trial (FOCUS) for Adults with Attention Deficit Hyperactivity Disorder
Shots:
- The first patient has been dosed in the P-III trial (FOCUS) evaluating the efficacy and safety of solriamfetol (150 or 300mg) vs PBO in a ratio (1:1:1) in ~ 450 patients with ADHD for 6wks.
- The 1EPs of the study will be changed in the adult ADHD investigator symptom report scale (AISRS)
- Solriamfetol, a dopamine and norepinephrine reuptake inhibitor. Additionally, Solriamfetol has agonist action at the 5HT1a and trace amine-associated receptor 1 (TAAR1) receptors, according to in vitro studies
Ref: GlobeNewswire | Image: Axsome Therapeutics
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
